Novartis Venture Fund
Novartis Venture Fund is a venture capital firm focused on companies that develop novel therapeutics and platforms.
Business Model:
Revenue: $34.4M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Novartis Venture Fund Information
Geographic Data
Address: 355 Main St
City: Cambridge
State: MA
Zip: 02142
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Twitter
Linkedin
Crunchbase
Metrics
9,316,027Website Global Rank
166Website Monthly Traffic
Twitter Followers
Description
Our primary focus is on the development of novel therapeutics and platforms. We balance the therapeutic focus with investments in medical devices, diagnostics or drug delivery systems. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency in the program. We prefer to have our initial investment at the early stage to build the company and follow with additional investment in pace with the company:tm:s progress. We continue our approach of larger focused investments and anticipate total investments up to USD 30 to 50 mio per company over its life, but it can be as little as 100&s;000 USD to get started. We will increase our activities to lead or co-lead deals further and remain open to participate in larger syndicates. Sectors New therapeutics &a; platforms Medical devices/implants Diagnostics/biomarkers Drug delivery/biopolymers Geography USA/Canada Europe Switzerland Asia/Pacific
Contact Phone:
+16178713536
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 9/2018 | Galera Therapeutics | Series C | 70M |
| 4/2014 | Alios BioPharma | Series B | 41M |
| 8/2004 | GlycoMimetics | Series A | 5.1M |
| 2/2016 | Galera Therapeutics | Series B | 0 |
| 7/2017 | NeuroVia | Series A | 14M |
| 6/2006 | GlycoMimetics | Series B | 0 |
| 8/2014 | Galera Therapeutics | Series A | 4.7M |
| 3/2007 | Phenomix | Series C | 55M |
| 4/2015 | Nabriva Therapeutics | Series B | 0 |
| 10/2009 | Nabriva Therapeutics | Venture Round | 0 |
| 11/2005 | PTC Therapeutics | Private Equity Round | 26.6M |
| 6/2007 | Aileron Therapeutics | Series B | 7M |
| 6/2009 | Alios BioPharma | Series A | 24M |
| 4/2007 | Protemix | Series A | 14.5M |
| 7/2009 | Avila Therapeutics | Series B | 30M |
| 4/2012 | Advanced Animal Diagnostics | Series B | 4M |
| 5/2009 | NovImmune | Venture Round | 0 |
| 6/2009 | Opsona | Series B | 4.6M |
| 9/2016 | Inflazome | Series A | 17M |
| 10/2013 | Opsona | Series C | 0 |
| 4/2013 | Opsona | Series C | 0 |
| 3/2022 | Epsilogen | Series B | 0 |
| 12/2012 | Bicycle Therapeutics | Venture Round | 6M |
| 9/2020 | ESCAPE Bio | Venture Round | 73M |
| 10/2020 | Rappta Therapeutics | Series A | 10.6M |
| 10/2014 | Forendo Pharma | Series A | 0 |
| 7/2017 | ESCAPE Bio | Series A | 63M |
| 2/2006 | Catalyst Biosciences | Series B | 30M |
| 8/2004 | Evolva | Series A | 14.8M |
| 4/2008 | Aileron Therapeutics | Series C | 10.5M |
| 6/2009 | Aileron Therapeutics | Series D | 40M |
| 1/2018 | Expansion Therapeutics | Series A | 55.3M |
| 12/2021 | IKAS Industrial Automation | Series B | 0 |
| 9/2022 | Capstan Therapeutics | Series A | 102M |
| 4/2018 | Enterprise Therapeutics | Series B | 41.3M |
| 8/2020 | ImmPACT Bio | Series A | 0 |
| 8/2012 | Sorbent Therapeutics | Series C | 18.1M |
| 12/2018 | Annexon Biosciences | Series C | 75M |
| 6/2016 | Annexon Biosciences | Series B | 44M |
| 9/2011 | Eledon Pharmaceuticals | Series D | 23M |
| 4/2013 | Catalyst Biosciences | Post-IPO Equity | 5.1M |
| 3/2011 | Euthymics Bioscience | Series A | 4M |
| 8/2006 | ESBATech | Series B | 41M |
| 10/2014 | Bicycle Therapeutics | Series A | 32M |
| 6/2002 | Infinity Pharmaceuticals | Series B | 0 |
| 11/2022 | DJEL | Venture Round | 139.4M |
| 1/2015 | Binx Health | Series C | 0 |
| 1/2016 | Adicet Bio | Series A | 51M |
| 2/2007 | Omeros | Series E | 0 |
| 3/2015 | Galera Therapeutics | Series A | 4.7M |
| 12/2005 | Santhera Pharmaceuticals | Series B | 0 |
| 5/2021 | Soteria Biotherapeutics | Series A | 42M |
| 11/2021 | Capstan Therapeutics | Seed Round | 63M |
| 3/2010 | Immune Targeting Systems | Series A | 13.2M |
| 6/2006 | NovImmune | Series B | 0 |
| 7/2011 | Binx Health | Series B | 27.1M |
| 3/2012 | ImaginAb | Series A | 12.5M |
| 10/2001 | Cylene Pharmaceuticals | Series A | 3.5M |
| 10/2009 | Bicycle Therapeutics | Seed Round | - |
| 10/2014 | Quartet Medicine | Series A | 17M |
| 10/2013 | Merus | Series B | 42.2M |
| 11/2022 | CatalYm | Series C | 0 |
| 12/2013 | Covagen | Series B | 0 |
| 12/2021 | Anaveon | Series B | 0 |
| 9/2019 | Adicet Bio | Series B | 0 |
| 3/2005 | Evolva | Series A | 2.6M |
| 7/2009 | Intellikine | Series B | 51M |
| 8/2008 | ESBATech | Series B | 22M |
| 12/2008 | Catalyst Biosciences | Post-IPO Equity | 40M |
| 6/2007 | Cequent Pharmaceuticals | Series A | 9M |
| 8/2004 | AGY Therapeutics | Series C | 9M |
| 5/2014 | Anokion | Series A | 37.5M |
| 6/2017 | Bicycle Therapeutics | Series B | 52M |
| 11/2020 | Catalym | Series B | 59.3M |
| 5/2019 | Twentyeight-Seven Therapeutics | Series A | 15M |
| 3/2021 | Amphista Therapeutics | Series B | 0 |
| 4/2015 | Merus | Series C | 79.1M |
| 12/2017 | Aelin Therapeutics | Series A | 31.8M |
| 8/2011 | Pulmatrix | Series B | 14M |
| 11/2009 | Pulmatrix | Series B | 30.2M |
| 1/2010 | MicroCHIPS | Venture Round | 16.5M |
| 8/2014 | YourBio Health | Series B | 16M |
| 12/2015 | Effector Therapeutics | Series B | 40M |
| 1/2019 | Ribon Therapeutics | Series B | 65M |
| 11/2013 | Aerpio Pharmaceuticals | Series A | 0 |
| 4/2020 | FoRx Therapeutics | Seed Round | 10.8M |
| 5/2019 | Cala Health | Series C | 0 |
| 12/2009 | GlycoMimetics | Series C | 0 |
| 12/2012 | Galera Therapeutics | Series A | 11M |
| 8/2018 | Akouos | Series A | 25.1M |
| 10/2009 | Covagen | Seed Round | - |
| 11/2010 | Covagen | Series A | 6.3M |
| 1/2017 | Binx Health | Series D | 0 |
| 10/2004 | Miikana Therapeutics | Series A | 3M |
| 3/2008 | LigoCyte Pharmaceuticals | Series C | 29.5M |
| 1/2009 | Intradigm Corporation | Series B | 0 |
| 12/2006 | Evolva | Series A | 10.3M |
| 12/2008 | Diagnoplex | Series A | 8.3M |
| 10/2014 | Aileron Therapeutics | Series E | 33M |
| 1/2021 | TScan Therapeutics | Series C | 100M |
| 12/2009 | FORMA Therapeutics | Series B | 3M |
| 4/2011 | ProCertus BioPharm | Series A | 1.7M |
| 8/2010 | Anchor Therapeutics | Series B | 10M |
| 4/2008 | FORMA Therapeutics | Series A | 4M |
| 12/2004 | Amphora Discovery | Series C | 20M |
| 3/2020 | Akouos | Series B | 105M |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 9/2018 | Forendo Pharma | Venture Round | 0 |
| 7/2019 | TScan Therapeutics | Series B | - |
| 4/2013 | GenSight Biologics | Series A | 41.7M |
| 8/2008 | Proteostasis Therapeutics | Series A | 45M |
| 5/2006 | Foldrx Pharmaceuticals | Series B | 43M |
| 7/2009 | Symetis | Series B | 0 |
| 4/2014 | Binx Health | Series B | 0 |
| 1/2010 | Cellerix | Series C | 37.7M |
| 11/2009 | Cellerix | Series B | 40.5M |
| 9/2007 | Cellerix | Series B | 37.2M |
| 5/2017 | Vivet Therapeutics | Series A | 41.2M |
| 5/2015 | Realeve | Series D | 38M |
| 9/2020 | Fore Biotherapeutics | Series C | 57M |
| 6/2021 | Ribon Therapeutics | Series C | 0 |
| 10/2021 | Exo Therapeutics | Series B | 0 |
| 12/2019 | Arctos Medical | Seed Round | 0 |
| 4/2007 | MicroCHIPS | Venture Round | 13.4M |
| 3/2011 | Advanced Animal Diagnostics | Series B | 11M |
| 11/2009 | Oxagen | Series C | 0 |
| 12/2014 | Annexon Biosciences | Series A | 34M |
| 9/2019 | Anokion | Series B | 40M |
| 4/2018 | Zikani Therapeutics | Venture Round | 0 |
| 5/2009 | Visiogen | Series D | 40M |
| 12/2020 | Exo Therapeutics | Series A | 25M |
| 9/2015 | Proteostasis Therapeutics | Series B | 37M |
| 1/2001 | Acorda Therapeutics | Series A | 0 |
| 2/2005 | Covalys Biosciences | Series B | 2.6M |
| 9/2012 | F2G | Equity | 30M |
| 3/2016 | Bionano Genomics | Series D | 9.9M |
| 7/2007 | Ablation Frontiers | Series C | 0 |
| 9/2012 | FORMA Therapeutics | Series C | 10M |
| 5/2000 | NovImmune | Series A | 14M |
| 6/2013 | Akebia Therapeutics | Series C | 0 |
| 11/2004 | Symetis | Series A | 9.6M |
| 5/2013 | Eledon Pharmaceuticals | Series E | 35.5M |
| 12/2009 | FORMA Therapeutics | Series B | 25.5M |
| 6/2016 | F2G | Series E | 60M |
| 9/2021 | Expansion Therapeutics | Series B | 80M |
| 7/2015 | Ra Pharmaceuticals | Series B | 58.5M |
| 8/2020 | GentiBio | Seed Round | 20M |
| 12/2006 | Aileron Therapeutics | Series A | 7M |
| 9/2016 | Rox Medical | Series E | 40M |
| 1/2013 | Aileron Therapeutics | Series D | 12M |
| 5/2014 | ImaginAb | Series B | 21M |
| 1/2019 | Occlufit | Venture Round | - |
| 4/2013 | Advanced Animal Diagnostics | Series B | 6M |
| 6/2010 | Foldrx Pharmaceuticals | Venture Round | 29M |
| 2/2015 | Altimmune | Post-IPO Equity | 16M |
| 10/2015 | Galera Therapeutics | Series B | 37M |
| 7/2010 | Euthymics Bioscience | Series A | 24M |
| 11/2013 | Aileron Therapeutics | Series E | 30M |
| 2/2009 | Alios BioPharma | Series A | 8.4M |
| 8/2019 | Renovacor | Series A | 11M |
| 5/2007 | ProCertus BioPharm | Series A | 2.3M |
| 7/2009 | ProCertus BioPharm | Venture Round | 2.1M |
| 7/2001 | Nereus Pharmaceuticals | Series B | 23.6M |
| 7/2007 | Neovacs | Venture Round | 17.9M |
| 6/2009 | Eledon Pharmaceuticals | Series D | 22M |
| 10/2006 | Biofisica | Series A | 5M |
| 7/2007 | Immune Targeting Systems | Series A | 7.1M |
| 1/2006 | EraGen Biosciences | Series A | 12M |
| 10/2012 | Thesan Pharmaceuticals | Series A | 16M |
| 1/2020 | TScan Therapeutics | Series B | 35M |
| 12/2009 | Evolva | Post-IPO Equity | 27.5M |
| 5/2020 | mPharma | Series C | 0 |
| 2/2019 | Anaveon | Series A | 35M |
| 11/2014 | Bionano Genomics | Series C | 0 |
| 4/2011 | Akebia Therapeutics | Series B | 0 |
| 9/2010 | Cylene Pharmaceuticals | Series D | 12M |
| 9/2004 | Nura | Series A | 9.5M |
| 11/2021 | Kedalion Therapeutics | Series B | - |
| 5/2014 | Sorbent Therapeutics | Series D | 0 |
| 6/2011 | Sorbent Therapeutics | Series B | 0 |
| 7/2009 | Viamet Pharmaceuticals | Series B | 25M |
| 9/2018 | Twentyeight-Seven Therapeutics | Series A | 65M |
| 7/2009 | Akebia Therapeutics | Series A | 25M |
| 5/2003 | GlycoMimetics | Series A | 4.3M |
| 8/2021 | Immunitas Therapeutics | Series B | 0 |
| 10/2009 | Evolva | Series B | 27.8M |
| 10/2014 | Viamet Pharma | Series D | 60M |
| 8/2018 | Artios Pharma | Series B | 0 |
| 7/2011 | Myopowers Medical Technologies | Series B | 16M |
| 6/2015 | Myopowers Medical Technologies | Series C | 5.1M |
| 2/2012 | Celladon | Venture Round | 43M |
| 8/2016 | Bionano Genomics | Series D | 31.7M |
| 3/2005 | TorreyPines Therapeutics | Series C | 0 |
| 10/2005 | Nereus Pharmaceuticals | Series D | 0 |
| 6/2007 | BioRelix | Series A | 25.8M |
| 3/2023 | Mediar Therapeutics | Series A | 0 |
| 2/2009 | Heptares Therapeutics | Series A | 30M |
| 6/2015 | Realeve | Series D | 43.2M |
| 12/2020 | Faze Medicines | Series A | 81M |
| 2/2022 | Splice Bio | Series A | 0 |
| 6/2023 | Tagworks Pharmaceuticals | Series A | 65M |
| 5/2001 | AGY | Series B | 13M |
| 1/2018 | Oculis | Series B | 20.5M |
| 3/2023 | Oculis | Post-IPO Equity | 0 |
| 11/2003 | Roche Glycart | Series A | 13.6M |
| 6/2023 | Tagworks Pharmaceuticals | Series A | 0 |
| 9/2021 | Flywheel.io | Series C | 0 |
| 8/2006 | Kemia | Series C | 0 |
| 7/2021 | Artios Pharma | Series C | 0 |
| 5/2002 | ESBATech | Series A | 0 |
| 5/2002 | Kalypsys | Series A | 42M |
| 2/2014 | Aeglea BioTherapeutics | Series A | 0 |
| 7/2015 | GenSight Biologics | Series B | 0 |
| 5/2021 | Oculis | Series C | 0 |
| 6/2015 | Kanyos Bio | Venture Round | 16.4M |
| 7/2019 | Forendo Pharma | Venture Round | 0 |
| 2/2006 | EyeSense AG | Series A | 0 |
| 10/2002 | MerLion Pharma | Series A | 0 |
| 1/2010 | Merus | Series B | 0 |
| 3/2007 | Okairos | Series A | 9.6M |
| 2/2015 | Merganser Biotech | Series A | 28M |
| 5/2001 | Polyphor | Venture Round | 9.3M |
| 11/2006 | Intradigm Corporation | Series A | 16M |
| 6/2005 | Amphora Discovery | Series D | 9.6M |
| 2/2008 | Biofisica | Venture Round | 2.4M |
| 2/2007 | Trellis Bioscience | Series B | 10M |
| 11/2021 | LOQUS23 THERAPEUTICS | Seed Round | 0 |
| 3/2015 | Zikani Therapeutics | Series A | 22M |
| 5/2017 | Lemonaid Health | Series A | 0 |
| 10/2011 | Realeve | Series C | 32M |
| 3/2017 | Aerpio Pharmaceuticals | Venture Round | 0 |
| 6/2007 | Tepha | Series B | 0 |
| 1/2022 | ImmPACT Bio | Series B | 0 |
| 3/2015 | Aeglea BioTherapeutics | Series B | 44M |
| 4/2014 | Aerpio Pharmaceuticals | Series C | 0 |
| 1/2017 | Cavion | Series A | 0 |
| 8/2021 | GentiBio | Series A | 157M |
| 10/2012 | Neurovance | Venture Round | 7M |
| 4/2014 | Neurovance | Series A | 6.3M |
| 3/2012 | BioRelix | Venture Round | 2.6M |
| 11/2007 | Ascent Therapeutics | Series A | 19M |
| 5/2013 | Effector Therapeutics | Series A | 45M |
| 6/2010 | NanoPowers | Series A | 0 |
| 4/2006 | Sirtris Pharmaceuticals | Series C | 37M |
| 9/2020 | Novellus | Series C | 57M |
| 9/2009 | PharmAbcine | Series A | 6M |
| 1/2000 | Viron Therapeutics | Series A | - |
| 2/2014 | Thesan Pharmaceuticals | Series B | 49M |
| 3/2022 | Epsilogen | Series B | 0 |
| 2/2022 | Splice Bio | Series A | 0 |
| 1/2022 | ImmPACT Bio | Series B | 0 |
| 12/2021 | IKAS Industrial Automation | Series B | 0 |
| 12/2021 | Anaveon | Series B | 0 |
| 11/2021 | LOQUS23 THERAPEUTICS | Seed Round | 0 |
| 11/2021 | Kedalion Therapeutics | Series B | - |
| 10/2021 | Exo Therapeutics | Series B | 0 |
| 9/2021 | Expansion Therapeutics | Series B | 0 |
| 9/2021 | Flywheel.io | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
